<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519516</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH174-0816/I</org_study_id>
    <nct_id>NCT03519516</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects</brief_title>
  <acronym>PRO-174/I</acronym>
  <official_title>Phase I Clinical Trial, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-174 Versus Sophixín Ofteno®, Elaborated by Laboratorios Sophia on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic solution
      PRO-174 versus Sophixín Ofteno®, elaborated by Laboratorios Sophia, S.A. of C.V. on the
      ocular surface of ophthalmologically and clinically healthy subjects.

      Goals:

      To evaluate the safety and tolerability of the formulation PRO-174 manufactured by
      Laboratorios Sophia, S.A. of C.V. on the ocular surface of clinically healthy subjects.

      Hypothesis:

      The ophthalmic solution PRO-174 presents a safety and tolerability profile similar to the
      comparator in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic solution
      PRO-174 versus Sophixín Ofteno®, elaborated by Laboratorios Sophia, S.A. of C.V. on the
      ocular surface of ophthalmologically and clinically healthy subjects.

      Goals:

      Methodology:

      Phase I clinical trial, controlled, of parallel groups, double blind, randomized,
      exploratory.

      Number of patients:

      30 subjects, divided into 2 groups [15 subjects (30 eyes) exposed per group]

      Test product, dose and route of administration, lot number:

        -  PRO-174. Levofloxacin 0.5% ophthalmic solution. Prepared by Laboratorios Sophia, S.A. of
           C.V., Zapopan, Jalisco, Mexico.

        -  Dosage: 1 drop every 2 hours during the waking period (8 daily applications), on day 1
           and 2; continuing with 1 drop every 4 hours during the waking period (4 daily
           applications) from day 3 to 7. Both eyes.

        -  Route of administration: ophthalmic

      Duration of treatment: 7 days

      Statistical methodology:

      The data will be expressed with measures of central tendency: mean and standard deviation for
      the quantitative variables. The qualitative variables will be presented in frequencies and
      percentages. The statistical analysis will be carried out through the Mann-Whitney U test for
      the quantitative variables for the difference between the groups. The intra-group difference
      will be made with the Wilcoxon rank test. The difference between the qualitative variables
      will be analyzed by means of X2 (Chi2). An alpha ≤ 0.05 will be considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Actual">June 10, 2018</completion_date>
  <primary_completion_date type="Actual">May 25, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase I clinical trial, controlled, of parallel groups, double blind, randomized, exploratory.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The blinding will correspond to the research subject and the principal investigator. In addition, the statistical analysis will be carried out in a blinded manner for the partial and final analysis.
The masking will be done using boxes in the primary packaging identical in the two groups. Blinding for the research subject and the researcher will be done by replacing the commercial labels in the case of the comparator in the bottles and the use of identical labels that contain the allocation number.
Blinding may be opened in the following cases:
Presence of a serious adverse event.
Safety alarm due to the use of the drugs under study.
In case the sponsor determines it for any reason of security or other reason that considers pertinent.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events (EAS)</measure>
    <time_frame>during the 12 days of evaluation, including the safety call (day 12).</time_frame>
    <description>primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Burning (OB)</measure>
    <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
    <description>primary tolerability variable
Ocular burning is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
    <description>the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breakup Time (BUT)</measure>
    <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
    <description>breakup time lacrimal film is a continuous variable that will be measured in seconds, evaluating the time it takes to break it, is done by direct counting and the normality range and mayor to 10 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Epithelial Defects (ED) by Grade</measure>
    <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
    <description>The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade</measure>
    <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
    <description>Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Foreign Body Sensation (FBS) by Grade</measure>
    <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
    <description>Foreign body sensation is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes With Ocular Pruritus (P) by Grade</measure>
    <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
    <description>Ocular pruritus is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Eyes of Chemosis</measure>
    <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
    <description>The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Capacity</measure>
    <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
    <description>The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and higher scores indicate worse visual acuity.
Snellen Scale: 20/200, 20/100, 20/70, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10
only the denominator of the fraction of each case is reported and averaged per group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Conjunctivitis</condition>
  <condition>Conjunctivitis, Bacterial</condition>
  <arm_group>
    <arm_group_label>PRO-174</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sophixín Ofteno®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-174</intervention_name>
    <description>Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
    <arm_group_label>PRO-174</arm_group_label>
    <other_name>PRO174</other_name>
    <other_name>Levofloxacin Ophthalmic Solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sophixín Ofteno®</intervention_name>
    <description>Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
    <arm_group_label>Sophixín Ofteno®</arm_group_label>
    <other_name>Ciprofloxacin Ophthalmic solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Systemically and ophthalmologically healthy subjects evaluated during the clinical
             history.

          -  Age between 18 to 45 years.

          -  Both genders.

          -  Blood tests (complete blood count, blood chemistry of three elements and liver
             function tests) within normal parameters specified by the reference laboratory with a
             lower and upper margin of 10%.

          -  Vital signs within normal parameters. (Vital signs at rest: blood pressure ≤ 139/89
             mmHg, heart rate 60 -100 beats per minute and respiratory rate of 12-24 breaths per
             minute).

          -  Visual capacity 20/30 or better, in both eyes.

          -  Intraocular pressure ≥11 and ≤ 21 mmHg.

        Exclusion Criteria:

        General criteria

          -  Subjects with a history of hypersensitivity to any of the components of the research
             products.

          -  Subject users of topical ophthalmic medications of any pharmacological group.

          -  Subject users of medication by any other route of administration.

          -  Pregnant or lactating women.

          -  Women of childbearing age, who do not ensure a hormonal contraceptive method or
             intrauterine device during the study period or without a history of bilateral tubal
             obstruction, oophorectomy or hysterectomy; as fertile age we understand women who have
             not had their menopause, defined as 12 months since the last menstruation in women
             over 40 years.

          -  Subjects with participation in clinical research studies 90 days prior to inclusion in
             the present study.

          -  Diagnosis of liver disease or elevation to three times the normal upper value of any
             of the following liver enzymes: aspartate transferase (AST), alanine transferase (ALT)
             or bilirubin.

          -  Inability to attend or answer the evaluations made in each of the visits.

          -  Positive smoking (specified as cigarette consumption regardless of amount and
             frequency)

          -  Positive alcoholism (specified as the consumption of alcoholic beverages, regardless
             of quantity and frequency, during the study intervention period).

          -  Contact lens users.

          -  An occlusive iridocorneal angle, defined as a trabecular mesh visible at less than 90
             ° from the angular circumference to gonioscopy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo Baiza Durán, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Sophia S.A de C.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Private Medical Offices</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <results_first_submitted>September 11, 2018</results_first_submitted>
  <results_first_submitted_qc>October 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2019</results_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ocular antibiotic</keyword>
  <keyword>quinolone</keyword>
  <keyword>levofloxacin</keyword>
  <keyword>ophthalmic antibiotic</keyword>
  <keyword>antibiotic in drops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis, Bacterial</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 18, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT03519516/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PRO-174</title>
          <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
        </group>
        <group group_id="P2">
          <title>Sophixín Ofteno®</title>
          <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ophthalmologically and clinically healthy</population>
      <group_list>
        <group group_id="B1">
          <title>PRO-174</title>
          <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
        </group>
        <group group_id="B2">
          <title>Sophixín Ofteno®</title>
          <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.67" spread="4.15"/>
                    <measurement group_id="B2" value="28.93" spread="9.38"/>
                    <measurement group_id="B3" value="26.3" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Adverse Events (EAS)</title>
        <description>primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent.</description>
        <time_frame>during the 12 days of evaluation, including the safety call (day 12).</time_frame>
        <population>the analysis of the population was by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (EAS)</title>
          <description>primary security variable the adverse events will be evaluated with a scale of Present / Absent, it is a nominal variable, the normal value is absent.</description>
          <population>the analysis of the population was by protocol</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it is considered as noninferiority if there is no difference greater than twenty percent between both medications</non_inferiority_desc>
            <p_value>0.749</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Burning (OB)</title>
        <description>primary tolerability variable
Ocular burning is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.</description>
        <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
        <population>the analysis of the study population was by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Burning (OB)</title>
          <description>primary tolerability variable
Ocular burning is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.</description>
          <population>the analysis of the study population was by protocol</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it is considered as noninferiority if there is no difference greater than twenty percent between both medications</non_inferiority_desc>
            <p_value>0.041</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure (IOP)</title>
        <description>the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg</description>
        <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
        <population>The study population was analyzed by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <description>the intraocular pressure will be evaluated by means of the Goldman applanation tonometry whose unit of measurement is millimeters of mercury (mmHg), it is a continuous variable and its normality range is between 11 - 21 mmHg</description>
          <population>The study population was analyzed by protocol</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.53" spread="1.0"/>
                    <measurement group_id="O2" value="12.68" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it is considered as noninferiority if there is no difference greater than twenty percent between both medications</non_inferiority_desc>
            <p_value>0.694</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breakup Time (BUT)</title>
        <description>breakup time lacrimal film is a continuous variable that will be measured in seconds, evaluating the time it takes to break it, is done by direct counting and the normality range and mayor to 10 seconds.</description>
        <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
        <population>The study population was analyzed by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Breakup Time (BUT)</title>
          <description>breakup time lacrimal film is a continuous variable that will be measured in seconds, evaluating the time it takes to break it, is done by direct counting and the normality range and mayor to 10 seconds.</description>
          <population>The study population was analyzed by protocol</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.27" spread="2.7"/>
                    <measurement group_id="O2" value="15.79" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it is considered as noninferiority if there is no difference greater than twenty percent between both medications</non_inferiority_desc>
            <p_value>0.495</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Epithelial Defects (ED) by Grade</title>
        <description>The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
        <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
        <population>The study population was analyzed by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Epithelial Defects (ED) by Grade</title>
          <description>The epithelial defects will be evaluated by means of two stains, green lysine and fluorescein, it is a discrete variable that will be realized by direct observation, it will be staged according to the degrees of the oxford scale that go from 0 to 5 (0-V) according to its severity, where 0 is the normal lower limit and 5 the upper limit of defects.</description>
          <population>The study population was analyzed by protocol</population>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Green lissamine grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Green lissamine grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>luorescein grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fluorescein grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it is considered as noninferiority if there is no difference greater than twenty percent between both medications</non_inferiority_desc>
            <p_value>0.492</p_value>
            <p_value_desc>statistical analysis between groups for final visit with green lissamine</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it is considered as noninferiority if there is no difference greater than twenty percent between both medications</non_inferiority_desc>
            <p_value>0.238</p_value>
            <p_value_desc>statistical analysis between groups for final visit with fluorescein</p_value_desc>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade</title>
        <description>Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.</description>
        <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
        <population>The study population was analyzed by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Conjunctival Hyperemia (CH) by Grade</title>
          <description>Conjunctival hyperemia will be evaluated as an ordinal variable, by direct observation and staged using the Efron scale as Normal / Very Light / Mild / Moderate / Severe. Based on this scale, the normal and mild stages are considered without pathologies or normal. Mild, moderate and severe are considered pathological.</description>
          <population>The study population was analyzed by protocol</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7"/>
                    <measurement group_id="O2" value="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>very mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it is considered as noninferiority if there is no difference greater than twenty percent between both medications</non_inferiority_desc>
            <p_value>0.213</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Foreign Body Sensation (FBS) by Grade</title>
        <description>Foreign body sensation is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.</description>
        <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
        <population>The study population was analyzed by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Foreign Body Sensation (FBS) by Grade</title>
          <description>Foreign body sensation is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.</description>
          <population>The study population was analyzed by protocol</population>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes With Ocular Pruritus (P) by Grade</title>
        <description>Ocular pruritus is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.</description>
        <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
        <population>The study population was analyzed by protocol grade 1</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes With Ocular Pruritus (P) by Grade</title>
          <description>Ocular pruritus is a nominal variable that will be evaluated by direct questioning to the research subject, then it will be staged according to the following scale:
Severity: Absent, very mild, mild, moderate and severe, where the normality of severity is absent.</description>
          <population>The study population was analyzed by protocol grade 1</population>
          <units>number of eyes with Ocular pruritus</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it is considered as noninferiority if there is no difference greater than twenty percent between both medications</non_inferiority_desc>
            <p_value>0.741</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Eyes of Chemosis</title>
        <description>The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.</description>
        <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
        <population>the statistical analysis of the sample was performed by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eyes of Chemosis</title>
          <description>The chemosis will be evaluated, as a nominal variable, by direct observation and it will be staged as present and absent, where the normality is that said variable is absent.</description>
          <population>the statistical analysis of the sample was performed by protocol</population>
          <units>eyes</units>
          <param>Number</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Capacity</title>
        <description>The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and higher scores indicate worse visual acuity.
Snellen Scale: 20/200, 20/100, 20/70, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10
only the denominator of the fraction of each case is reported and averaged per group.</description>
        <time_frame>will be evaluated at the end of the treatment at the final visit (day 7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-174</title>
            <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
          <group group_id="O2">
            <title>Sophixín Ofteno®</title>
            <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Capacity</title>
          <description>The visual capacity variable will be reported using as a unit of measure a fraction, this is taken from a visual test with the Snellen primer, it is a Nominal type variable. where the optimal vision is 20/20 and higher scores indicate worse visual acuity.
Snellen Scale: 20/200, 20/100, 20/70, 20/50, 20/40, 20/30, 20/25, 20/20, 20/15, 20/12, 20/10
only the denominator of the fraction of each case is reported and averaged per group.</description>
          <units>units on a scale (snellen)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="2.17"/>
                    <measurement group_id="O2" value="20" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The study drug is considered non-inferior with respect to the comparator if there are no differences above twenty percent</non_inferiority_desc>
            <p_value>0.110</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>the adverse events were evaluated for a period of 13 days, from the baseline visit (day one) until the safety call three days after the last application of the study medication (day 13). MedDRA (V. 20.1)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PRO-174</title>
          <description>Active ingredient: Levofloxacin 0.5%
o Dosage: 1 drop in both eyes, 8 times a day during the waking period
PRO-174: Pharmaceutical form: ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
        </group>
        <group group_id="E2">
          <title>Sophixín Ofteno®</title>
          <description>o Dosage: 1 drop in both eyes, 8 times a day during the waking period
Sophixín Ofteno®: o Active substance: Ciprofloxacin 0.3%
Pharmaceutical form: Ophthalmic solution
Prepared by: Laboratorios Sophia, S.A. of C.V.
Description of the solution: transparent solution, free of visible particles.
Description of container: sterile multi-dose bottle</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>ocular burning</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>itching in the eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>conjunctival hyperemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>tearing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>only the sponsor has the decision to disseminate or publish the information obtained from the investigation and the PIs involved must submit a formal request to the sponsor if they are willing to disseminate or publish such information, they may only publish them if they have the written authorization of the sponsor (Laboratoios Sophia S.A. de C.V.).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ricardo Alonso Llamas Velázquez (clinical safety pharmacologist)</name_or_title>
      <organization>Laboratorios Sophia</organization>
      <phone>+52 (33) 3001 4200 ext 1259</phone>
      <email>ricardo.llamas@sophia.com.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

